688298.SH
东方生物
SSE · Healthcare · Medical - Specialties · CN
CNY 18.71
−3.71%Year over year
Reported trailing growth
- Revenue
- +20.9%
- EBITDA
- —
- EBIT
- +13.1%
- EPS
- +1.3%
- Free cash flow
- +55.4%
- Operating cash flow
- +11.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -52.4%
- EBITDA
- -1.1%
- EBIT
- -0.6%
- Net income
- -8.4%
- EPS
- -10.8%
- Free cash flow
- +60.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026